Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8273)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 28, 2021 (publication date) through Dec 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Muñoz AE, Pollarsky FD, Marino M, Cartier M, Vázquez H, Salgado P, Romero G. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy. World J Gastroenterol 2021; 27(28): 4639-4652 [PMID: 34366626 DOI: 10.3748/wjg.v27.i28.4639] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i28/4639.htm |
| Number | Citing Articles |
| 1 |
Maxime Mallet, Cristina Alina Silaghi, Philippe Sultanik, Filomena Conti, Marika Rudler, Vlad Ratziu, Dominique Thabut, Raluca Pais. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology 2024; 80(5): 1270 doi: 10.1097/HEP.0000000000000456
|
| 2 |
Andrew S. Bell, Emma M. O’Connell, Falk W. Lohoff. Cholesterol. 2022; : 747 doi: 10.1016/B978-0-323-85857-1.00036-5
|
| 3 |
Alberto E. Muñoz, Enrique G. Rodger. Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology 2024; 80(1): E8 doi: 10.1097/HEP.0000000000000846
|
| 4 |
Spencer R Goble, Philippe Nyembo, Holly Rodin, George Konstantinides, Jesse Powell, Amanda J Noska. Statin Utilization Among Individuals Infected With Hepatitis C Virus: A Retrospective Cohort Study. Cureus 2023; doi: 10.7759/cureus.36049
|
| 5 |
文瑾 程. New Advances in the Treatment of Portal Hypertension and Its Complications in Cirrhosis. Advances in Clinical Medicine 2022; 12(03): 2192 doi: 10.12677/ACM.2022.123316
|
| 6 |
Katherine M. Cooper, Ami K. Patel, Christopher A. Zammitti, Ellen Murchie, Alessandro Colletta, Deepika Devuni. Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis. Journal of Clinical and Experimental Hepatology 2025; 15(2): 102427 doi: 10.1016/j.jceh.2024.102427
|
| 7 |
Zhenyu Wu, Lei Chen, Jing Chen, Chuanfang Chen. Liver Cirrhosis and Its Complications - Advances in Diagnosis and Management. 2024; doi: 10.5772/intechopen.1005466
|
| 8 |
Sara Armani, Andreas Geier, Thomas Forst, Uta Merle, David H. Alpers, Martin W. Lunnon. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions. British Journal of Clinical Pharmacology 2024; 90(4): 942 doi: 10.1111/bcp.15990
|
| 9 |
R. M. Lupachev, M. L. Maksimov. The use of statins and inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK 9) in patients with dyslipidemia. Glavvrač (Chief Medical Officer) 2024; (1): 20 doi: 10.33920/med-03-2401-02
|
| 10 |
Mohan Chandra Vinay Bharadwaj Gudiwada, Vinuthna Gaddam, Maheen Rahman, Jaswanth R Jasti, Paritaben Bhalodia, Sahas Reddy Jitta. High-Intensity Statin Therapy and Associated Rhabdomyolysis in Chronic Liver Disease: A Case Report and Review of Literature. Cureus 2023; doi: 10.7759/cureus.39150
|
| 11 |
Mar Gil, Lareen Khouri, Imma Raurell, Diana Rafael, Fernanda Andrade, Ibane Abasolo, Simo Schwartz, María Martínez-Gómez, María Teresa Salcedo, Juan Manuel Pericàs, Diana Hide, Mingxing Wei, Norman Metanis, Joan Genescà, María Martell. Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells. Pharmaceutics 2023; 15(10): 2463 doi: 10.3390/pharmaceutics15102463
|
| 12 |
John P. ONeill, Cathal S Clifford, Niamh P. Nolan, P. Aiden McCormick. Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis. Irish Journal of Medical Science (1971 -) 2023; 192(4): 1657 doi: 10.1007/s11845-022-03153-0
|
| 13 |
Carlos Sanz-Garcia, Yulia A. Nevzorova, Eduardo Martínez-Naves, Francisco Javier Cubero, Alejandro Hionides-Gutierrez, Jose Ramón Sañudo, Carlos Enrich, Carles Rentero, Pau Sancho-Bru, Ricardo U. Macías-Rodriguez, Astrid Ruiz-Margain, David Kershenobich-Stalnikowitz, Nestor R. Vargas, Alberto E. Muñoz, Helder I. Nakaya. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis. Gastroenterología y Hepatología (English Edition) 2023; 46(4): 322 doi: 10.1016/j.gastre.2022.05.010
|
| 14 |
Irina Gîrleanu, Anca Trifan, Laura Huiban, Cristina Muzîca, Oana Cristina Petrea, Ana Maria Sîngeap, Camelia Cojocariu, Stefan Chiriac, Tudor Cuciureanu, Irina Iuliana Costache, Carol Stanciu. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life 2022; 12(7): 1036 doi: 10.3390/life12071036
|
| 15 |
Ahmad Anouti, Thomas A Kerr, Mack C Mitchell, Thomas G Cotter. Advances in the management of alcohol-associated liver disease. Gastroenterology Report 2023; 12 doi: 10.1093/gastro/goae097
|
| 16 |
Carlos Sanz-Garcia, Yulia A. Nevzorova, Eduardo Martínez-Naves, Francisco Javier Cubero, Alejandro Hionides-Gutierrez, Jose Ramón Sañudo, Carlos Enrich, Carles Rentero, Pau Sancho-Bru, Ricardo U. Macías-Rodriguez, Astrid Ruiz-Margain, David Kershenobich-Stalnikowitz, Nestor R. Vargas, Alberto E. Muñoz, Helder I. Nakaya. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis. Gastroenterología y Hepatología 2023; 46(4): 322 doi: 10.1016/j.gastrohep.2022.05.012
|
| 17 |
Portal hypertension as an independent risk factor for cirrhotic cardiomyopathy: An investigation on its mechanism based on bioinformatics analysis. Portal Hypertension & Cirrhosis 2024; 3(4): 196 doi: 10.1002/poh2.88
|